# Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction

Study · id `cardio:ct-nct02789501` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02789501](<https://clinicaltrials.gov/study/NCT02789501>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02789501

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.

## Technical summary

Registry record NCT02789501. Randomized; single masking; primary purpose prevention. Start 2012-01 (registry gives no type); primary completion 2016-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 106 participants (enrolled count; ClinicalTrials.gov record NCT02789501, source copy `cardio:ctgov-nct02789501-2016-12-05`, retrieved 2026-10-26)
- Start date: 2012-01 (registry gives no type) (ClinicalTrials.gov record NCT02789501, source copy `cardio:ctgov-nct02789501-2016-12-05`, retrieved 2026-10-26)
- Primary completion: 2016-08 (actual) (ClinicalTrials.gov record NCT02789501, source copy `cardio:ctgov-nct02789501-2016-12-05`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: Austria (ClinicalTrials.gov record NCT02789501, source copy `cardio:ctgov-nct02789501-2016-12-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02789501-2016-12-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction
- Condition: Catheter Infections
- Condition: End-stage Renal Disease
- Intervention (Device): 4% citrate lock solution regimen
- Intervention (Device): TauroLock lock solution regimen
- Lead sponsor: Medical University of Vienna
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Medical University of Vienna (`cardio:org-medical-university-of-vienna`)

## Provenance

Content hash: 15aa16d1ed1da637ca4b47290cd18ed55b7552b679833e1375420cc96f35e139
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
